Clinical trials in neuroprotection

Progress in Brain Research

Volumn 173, Issue , 2008, Pages 323-335

  Whitcup, Scott M ^a,b  

^a ALLERGAN INC   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

Author keywords

endpoint; experimental design; glaucoma; neurodegenerative disease; neuroprotection; retina; visual function

Indexed keywords

ALPHA TOCOPHEROL; BRIMONIDINE; GAVESTINEL; MEMANTINE; NEUROPROTECTIVE AGENT; RETINOL; RILUZOLE; TIMOLOL;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL STUDY; CLINICAL TRIAL; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; METHODOLOGY; NERVE CELL DEGENERATION; NERVE DECOMPRESSION; NEUROPROTECTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; REVIEW; VISION; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

DISEASE PROGRESSION; ENDPOINT DETERMINATION; GLAUCOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OPTIC NERVE DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VISUAL FIELDS;

EID: 53049108766     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)01123-0     Document Type: Review

References (46)

1. Bensimon G., Lacomblex V., Meininger V., and ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 330 9 (1994) 585-591
2. Berson E.L., Rosner B., Sandberg M.A., Hayes K.C., Nicholson B.W., Weigel-DiFranco C., and Willett W. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch. Ophthalmol. 111 6 (1993) 761-772
3. Bodick N., Forette F., Hadler D., Harvey R.J., Leber P., McKeith I.G., Riekkinen P.J., Rossor M.N., Scheltens P., Shimohama S., Spiegel R., Tanaka S., Thal L.J., Urata Y., Whitehouse P., and Wilcock G. Protocols to demonstrate slowing of Alzheimer's disease progression. Position paper from the international working group on harmonization of dementia drug guidelines. The disease progression sub-group. Alzheimer Dis. Assoc. Discord. 11 3 (1997) 50-53
4. Boghen D.R., and Glaser J.S. Ischemic optic neuropathy. The clinical profile and history. Brain 98 4 (1975) 689-708
5. Bowd C., Zangwill L.M., Berry C.C., Blumenthal E.Z., Vasile C., Sanchez-Galeana C., Bosworth C.F., Sample P.A., and Weinreb R.N. Detecting early glaucoma by assessment of retinal nerve fiber layer thickness and visual function. Invest. Ophthalmol. Vis. Sci. 42 9 (2001) 1993-2003
6. Casson R., James B., Rubinstein A., and Ali H. Clinical comparison of frequency doubling technology perimetry and Humphrey perimetry. Br. J. Ophthalmol. 85 3 (2001) 360-362
7. Cello K.E., Nelson-Quigg J.M., and Johnson C.A. Frequency doubling technology perimetry for detection of glaucomatous visual field loss. Am. J. Ophthalmol. 129 3 (2000) 314-322
8. Charcot J.M. Lecons sur les maladies du systeme nerveux faites a la Salpetriere. Progr. Med. (Paris) 1 (1877) 213-242
9. Chohan M.O., and Iqbal K. From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease. J. Alzheimers Dis. 10 1 (2006) 81-87
10. Clarke C.E. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?. Mov. Disord. 19 5 (2004) 491-498
11. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 126 4 (1998) 487-497
12. Cosman K.M., Boyle L.L., and Porsteinsson A.P. Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opin. Pharmacother. 8 2 (2007) 203-214
13. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J. Neurochem. 42 1 (1984) 1-11
14. Heijl A., Leske M.C., Bengtsson B., Hyman L., Bengtsson B., Hussein M., and for Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120 10 (2002) 1268-1279
15. Holopigian K., Greenstein V., Seiple W., and Carr R.E. Rates of change differ among measures of visual function in patients with retinitis pigmentosa. Ophthalmology 103 (1996) 398-405
16. Hood D.C., Seiple W., Hologigian K., and Greenstein V. A comparison of the components of the multifocal and full-field ERGs. Vis. Neurosci. 14 3 (1997) 533-544
17. Hutchings N., Hosking S.L., Wild J.M., and Flanagan J.G. Long-term fluctuation in short-wavelength automated perimetry in glaucoma suspects and glaucoma patients. Invest. Ophthalmol. Vis. Sci. 42 10 (2001) 2332-2337
18. Johnson C.A. Recent developments in automated perimetry in glaucoma diagnosis and management. Curr. Opin. Ophthalmol. 13 2 (2002) 77-84
19. Johnson C.A., and Samuels S.J. Screening for glaucomatous visual field loss with frequency-doubling perimetry. Invest. Ophthalmol. Vis. Sci. 38 2 (1997) 413-425
20. Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P., Parrish II R.K., Wilson M.R., and Gordon M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120 6 (2002) 701-713
21. Kelman S.E., and Elman M.J. Optic nerve sheath decompression for nonarteritic ischemic optic neuropathy improves multiple visual function parameters. Arch. Ophthalmol. 109 5 (1991) 667-671
22. Klistorner A., and Graham S.L. Objective perimetry in glaucoma. Ophthalmology 107 12 (2000) 2283-2299
23. Landers J., Goldberg I., and Graham S. A comparison of short wavelength automated perimetry with frequency doubling perimetry for the early detection of visual loss in ocular hypertension. Clin. Experiment. Ophthalmol. 28 4 (2000) 248-252
24. Lichter P.R., Musch D.C., Gillespie B.W., Guire K.E., Janz N.K., Wren P.A., Mills R.P., and CIGTS Study Group. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology 108 11 (2001) 1943-1953
25. Mangione C.M., Lee P.P., Gutierrez P.R., Spritzer K., Berry S., Hays R.D., and National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch. Ophthalmol. 119 7 (2001) 1050-1058
26. Miglior S., Casula M., Guareschi M., Marchetti I., Iester M., and Orzalesi N. Clinical ability of Heidelberg retinal tomograph examination to detect glaucomatous visual field changes. Ophthalmology 108 9 (2001) 1621-1627
27. Miglior S., Zeyen T., Pfeiffer N., Cunha-Vaz J., Torri V., Adamsons I., and European Glaucoma Prevention Study (EGPS) Group. Results of the European Glaucoma Prevention Study. Ophthalmology 112 3 (2005) 366-375
28. Mitchell J.D., and Borasio G.D. Amyotrophic lateral sclerosis. Lancet 369 9578 (2007) 2031-2041
29. Mizoule J., Meldrum B., Mazadier M., Croucher M., Ollat C., Uzan A., Legrand J.J., Gueremy C., and Le Fur G. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission-I. Anticonvulsant properties. Neuropharmacology 24 8 (1985) 767-773
30. Pallàs M., and Camins A. Molecular and biochemical features in Alzheimer's disease. Curr. Pharm. Des. 12 33 (2006) 4389-4408
31. Plaitakis A., and Caroscio J.T. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 22 5 (1987) 575-579
32. Reisberg B., Doody R., Stöffler A., Schmitt F., Ferris S., Möbius H.J., and Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348 14 (2003) 1333-1341
33. Repka M.X., Savino P.J., Schatz N.J., and Sergott R.C. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am. J. Ophthalmol. 96 4 (1983) 478-483
34. Rothstein J.D., Martin L.J., and Kuncl R.W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 326 22 (1992) 1464-1468
35. Sacco R.L., DeRosa J.T., Haley Jr. E.D., Levin B., Ordronneau P., Phillips S.J., Rundek T., Snipes R.G., Thompson J.L., and Glycine Antagonist in Neuroprotection Americas Investigators. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 285 13 (2001) 1719-1728
36. Sackett D.L. Bias in analytic research. J. Chronic Dis. 32 1-2 (1979) 51-63
37. Sergott R.C., Cohen M.S., Bosley T.M., and Savino P.J. Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy. Arch. Ophthalmol. 107 12 (1989) 1743-1754
38. Spoor T.C., McHenry J.G., and Lau-Sickon L. Progressive and static nonarteritic ischemic optic neuropathy treated by optic nerve sheath decompression. Ophthalmology 100 3 (1993) 306-311
39. Spoor T.C., Wilkinson M.J., and Ramocki J.M. Optic nerve sheath decompression for the treatment of progressive nonarteritic ischemic optic neuropathy. Am. J. Ophthalmol. 111 4 (1991) 724-728
40. Sunness J.S., Schuchard R.A., Shen N., Rubin G.S., Dagnelie G., and Haselwood D.M. Landmark-driven fundus perimetry using the scanning laser ophthalmoscope. Invest. Ophthalmol. Vis. Sci. 36 9 (1995) 1863-1874
41. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., Gergel I., and Memanine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 3 (2004) 317-324
42. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130 4 (2000) 429-440
43. The Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. JAMA 273 8 (1995) 625-632
44. WoldeMussie E., Ruiz G., Wijono M., and Wheeler L.A. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest. Ophthalmol. Vis. Sci. 42 12 (2001) 2849-2855
45. Wollstein G., Garway-Heath D.F., Fontana L., and Hitchings R.A. Identifying early glaucomatous changes. Comparison between expert clinical assessment of optic disc photographs and confocal scanning ophthalmoscopy. Ophthalmology 107 12 (2000) 2272-2277
46. Zangwill L.M., Bowd C., Berry C.C., Williams J., Blumenthal E.Z., Sánchez-Galeana C.A., Vasile C., and Weinreb R.N. Discriminating between normal and glaucomatous eyes using the Heidelberg retina tomograph, GDx Nerve Fiber Analyzer, and Optical Coherence Tomograph. Arch. Ophthalmol. 119 7 (2001) 985-993